CI
TMO icon

CX Institutional’s Thermo Fisher Scientific TMO Stock Holding History

CX Institutional’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.69M Sell
5,462
-14,125
-72% -$8.39M 0.1% 192
2026
Q2 		$9.82M Buy
19,587
+2,307
+13% +$1.11M 0.28% 80
2026
Q1 		$8.49M Buy
17,280
+637
+4% +$346K 0.26% 87
2025
Q4 		$9.64M Sell
16,643
-173
-1% -$97.8K 0.29% 82
2025
Q3 		$8.16M Buy
16,816
+693
+4% +$323K 0.25% 96
2025
Q2 		$6.54M Buy
16,123
+5,967
+59% +$2.49M 0.23% 101
2025
Q1 		$5.05M Buy
10,156
+196
+2% +$106K 0.19% 122
2024
Q4 		$5.18M Buy
9,960
+2,062
+26% +$1.13M 0.21% 122
2024
Q3 		$4.89M Buy
7,898
+6,691
+554% +$3.96M 0.22% 127
2024
Q2 		$667K Buy
1,207
+13
+1% +$7.45K 0.03% 336
2024
Q1 		$694K Buy
1,194
+17
+1% +$9.54K 0.03% 327
2023
Q4 		$625K Buy
1,177
+222
+23% +$107K 0.03% 308
2023
Q3 		$483K Sell
955
-327
-26% -$174K 0.03% 330
2023
Q2 		$669K Buy
1,282
+85
+7% +$45.9K 0.03% 323
2023
Q1 		$685K Buy
1,197
+140
+13% +$78.9K 0.04% 323
2022
Q4 		$582K Buy
1,057
+441
+72% +$234K 0.04% 350
2022
Q3 		$312K Buy
616
+14
+2% +$7.83K 0.02% 387
2022
Q2 		$327K Sell
602
-25
-4% -$13.8K 0.02% 376
2022
Q1 		$370K Buy
627
+47
+8% +$27K 0.03% 290
2021
Q4 		$387K Buy
580
+31
+6% +$19.4K 0.03% 263
2021
Q3 		$314K Buy
549
+17
+3% +$9.33K 0.03% 312
2021
Q2 		$268K Buy
532
+15
+3% +$7.08K 0.02% 310
2021
Q1 		$236K Buy
517
+9
+2% +$4.3K 0.02% 288
2020
Q4 		$237K Buy
508
+26
+5% +$12.2K 0.02% 281
2020
Q3 		$213K Buy
482
+178
+59% +$73.5K 0.02% 258
2020
Q2 		$110K Buy
304
+22
+8% +$7.37K 0.01% 280
2020
Q1 		$80K Buy
282
+114
+68% +$35.9K 0.01% 287
2019
Q4 		$55K Hold
168
– – 0.01% 275
2019
Q3 		$49K Buy
168
+46
+38% +$13.2K 0.01% 299
2019
Q2 		$36K Sell
122
-9
-7% -$2.48K 0.01% 342
2019
Q1 		$36K Buy
+131
New +$32.6K 0.01% 348

Other funds holding TMO

DLA
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return
QPBE
Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AIM
Avity Investment Management Greenwich, Connecticut $1.6B AUM 32.15% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

CX Institutional's TMO Position: Q3 2026 in Review

CX Institutional reduced its Thermo Fisher Scientific (TMO) stake by 72% in Q3 2026, selling an estimated $8.39M and leaving 5,462 shares worth $3.69M. The position accounts for 0.1% of the portfolio, ranked #192.

CX Institutional first reported a position in TMO in Q1 2019 and has held it in 31 quarters since. The position peaked at $9.82M in Q2 2026. 134 funds tracked by Wall St. Rank hold TMO as of Q3 2026.

  • CX Institutional held 5,462 shares of Thermo Fisher Scientific worth $3.69M as of Q3 2026.
  • CX Institutional sold 14,125 Thermo Fisher Scientific shares in Q3 2026, an estimated $8.39M.
  • Thermo Fisher Scientific made up 0.1% of CX Institutional's portfolio in Q3 2026, its #192 holding.
  • CX Institutional first reported a position in Thermo Fisher Scientific in Q1 2019 and has held it in 31 quarters since.
  • CX Institutional's Thermo Fisher Scientific position peaked at $9.82M in Q2 2026.
  • 134 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.